Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Scilex Holding Company (SCLXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SCLXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $
1 Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.61% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.14 | 52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 |
52 Weeks Range 0.04 - 0.52 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -146.93% | Operating Margin (TTM) -557.51% |
Management Effectiveness
Return on Assets (TTM) -69.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4990167 |
Shares Outstanding - | Shares Floating 4990167 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Scilex Holding Company
Company Overview
History and Background
Scilex Holding Company is a biopharmaceutical company focused on acquiring, developing, and commercializing non-opioid therapies for patients with acute and chronic pain. Originally part of Sorrento Therapeutics, Scilex became an independent publicly traded company in 2022. It aims to address the opioid crisis by providing alternative pain management solutions.
Core Business Areas
- Pain Management: Focuses on developing and commercializing non-opioid pain management products, including ZTlido and SP-102 (SEMDEXAu2122).
Leadership and Structure
The leadership team includes Jaisim Shah (CEO). The organizational structure is typical of a biopharmaceutical company, with departments for research and development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- SP-102 (SEMDEXAu2122): A non-opioid injectable corticosteroid product candidate for the treatment of sciatica pain. Market share is projected once approved. Competitors include epidural steroid injections.
- ZTlido: A lidocaine topical system for the relief of post-herpetic neuralgia (PHN). Market share data is not publicly available. Competitors include Lidoderm (Endo International) and generic lidocaine patches.
Market Dynamics
Industry Overview
The pain management market is large and growing, driven by an aging population and increasing prevalence of chronic pain conditions. There's a growing demand for non-opioid alternatives due to the opioid crisis.
Positioning
Scilex positions itself as a provider of non-opioid pain management solutions, targeting a segment of the market seeking alternatives to traditional opioid therapies. Its competitive advantage lies in its focus on non-opioid products and its novel drug delivery technologies.
Total Addressable Market (TAM)
The total addressable market for pain management is estimated to be billions of dollars. Scilex is positioned to capture a portion of this TAM by offering non-opioid alternatives to opioids.
Upturn SWOT Analysis
Strengths
- Focus on non-opioid pain management
- Novel drug delivery technologies
- ZTlido already on the market
- SP-102 potential approval
Weaknesses
- Limited product portfolio
- Reliance on successful clinical trials and regulatory approvals
- Smaller size compared to larger pharmaceutical companies
- Heavy debt burden
Opportunities
- Expanding product portfolio through acquisitions or in-licensing
- Partnering with larger pharmaceutical companies
- Increasing awareness of non-opioid pain management options
- Growing demand for alternatives to opioids
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Generic competition for ZTlido
- Failure of clinical trials for SP-102
Competitors and Market Share
Key Competitors
- Endo International (ENDP)
- Pacira BioSciences (PCRX)
- Assertio Holdings, Inc. (ASRT)
Competitive Landscape
Scilex faces competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its focus on non-opioid therapies and innovative delivery systems, but it must overcome challenges related to funding and scale.
Growth Trajectory and Initiatives
Historical Growth: Limited data available due to recent spin-off.
Future Projections: Future growth depends on the successful commercialization of SP-102 and expansion of the product portfolio.
Recent Initiatives: Focus on obtaining regulatory approval for SP-102 and managing debt.
Summary
Scilex Holding Company is a biopharmaceutical company focused on non-opioid pain management that has potential. ZTlido is on the market and SP-102 is undergoing trials. Scilex has a heavy debt burden and needs to manage its finances and gain regulatory approval for SP-102 to stay competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scilex Holding Company
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2021-03-08 | President, CEO & Director Mr. Jaisim Shah | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 111 | Website https://www.scilexholding.com |
Full time employees 111 | Website https://www.scilexholding.com | ||
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.